Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 21; p. 3468
• Main Authors: Hong, Chien-Tai, Chan, Lung, Chen, Kai-Yun, Lee, Hsun-Hua, Huang, Li-Kai, Yang, Yu-Chen S. H., Liu, Yun-Ru, Hu, Chaur-Jong
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2022; MDPI
• Subjects: Alzheimer's disease; Animals; Anti-Bacterial Agents - pharmacology; Antibiotics; Blood-brain barrier; Clinical trials; Dosage and administration; Drug therapy; FDA approval; Gastrointestinal Microbiome - physiology; Gene amplification; gut microbiota; Health aspects; IL-1β; Inflammation; Inflammation - drug therapy; Interleukin 6; Intestinal microflora; Laboratory animals; Mice; Microbiota; Microbiota (Symbiotic organisms); Microorganisms; Motor task performance; Movement disorders; Neurodegenerative diseases; Neuroprotection; Parkinson Disease - drug therapy; Parkinson's disease; Patients; Phylogenetics; Prebiotics; Probiotics; Proteins; Relative abundance; Rifaximin; Rifaximin - pharmacology; Rifaximin - therapeutic use; Taxonomy; Transgenic mice; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Veganism; Taiwan; St Louis Missouri; United States > US; inflammation; rifaximin; Parkinson’s disease; gut microbiota

Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota. The present study investigated the effect of rifaximin on gut microbiota and inflammation status in PD. The stud...